News releases

Please be advised that the information posted was accurate at the time of posting, but may be superseded by subsequent news releases.

To automatically receive future news releases, please go to the News subscription service page.

[2014] - 2013 - 2012 - 2011 - 2010 - 2009 - 2008 - 2007 - 2006 - 2005 - 2004 - 2003 - 2002

(click to view the full text)

April 9, 2014
Aeterna Zentaris: Poster Presentation at AACR Meeting Provides Rationale for New Therapeutic Opportunities in Oncology with Erk Inhibitors
April 1, 2014
Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego
March 28, 2014
Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for “At-the-Market” Common Share Issuance Programs
March 20, 2014
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2013 Financial and Operating Results
March 12, 2014
Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2013 Financial and Operating Results on March 20, 2014
February 4, 2014
Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer
February 3, 2014
Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin and Disorazol Z Conjugates at Upcoming International Symposium on GnRH
January 14, 2014
Aeterna Zentaris Announces Closing of US$13.2 Million Public Offering of Common Shares and Warrants
January 9, 2014
Aeterna Zentaris Announces Pricing of US$13.2 Million Public Offering of Common Shares and Warrants
January 8, 2014
Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants
January 6, 2014
Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by the FDA
January 3, 2014
Aeterna Zentaris Appoints Dr. Richard Sachse as Chief Scientific Officer